Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Macrogenics (NASDAQ:MGNX) reported its Q4 earnings results on Thursday, March 7, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Macrogenics missed estimated earnings by -400.0%, reporting an EPS of $-0.75 versus an estimate of $-0.15.
Revenue was down $62.38 million from the same period last year.
Last quarter the company beat on EPS by $0.38 which was followed by a 17.0% increase in the share price the next day.
Here's a look at Macrogenics's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -0.10 | -0.52 | 0.45 | 0.10 |
EPS Actual | 0.28 | 0.92 | -0.61 | 0.21 |
Revenue Estimate | 48.86M | 29.74M | 86.49M | 58.78M |
Revenue Actual | 10.40M | 13.14M | 24.50M | 73.10M |
To track all earnings releases for Macrogenics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: MGNX